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ABSTRACT 42 
Topical immune-response modifiers are established for actinic keratosis (AK) treatment, and 43 
efforts are underway to further improve their efficacy and safety.  We investigated the 44 
optimal dosing regimens of the TLR7/8 agonist resiquimod in terms of efficacy, safety, and 45 
tolerability. 46 
 47 
In a multi-centre, partly placebo-controlled (double-blind), clinical trial, we randomized 217 48 
patients with AK-lesions to 0.03% resiquimod gel once daily application 3 times weekly for 49 
4 weeks or 7 times within 2 weeks or 5 times in 1 week (Arms1/2/3) followed by a treatment-50 
free interval of 8 weeks and one repetition of the cycle.  In two additional arms (Arms4/5), 51 
patients applied either resiquimod gel 0.01% or 0.03% 3 times weekly up to a biological end-52 
point defined by skin erosion or for a maximum duration of 8 weeks.  Clearance was 53 
assessed clinically and histologically. 54 
 55 
Complete clinical clearance ranged from 56% to 85% with the highest rate observed in 56 
Arm2.  Resiquimod 0.03% gel was more effective than 0.01% gel.  Clearance rates in 57 
Arms1/2/3 were comparable and higher than with placebo and were reached with 24, 14 58 
and 10 gel applications.  128 (59%) patients experienced treatment-related adverse 59 
reactions. 60 
 61 
Resiquimod 0.03% gel is more effective than 0.01%.  The lower concentration and shorter 62 
duration are preferable from safety and tolerability perspectives.  The clinical response in 63 
Arms2/3 was reached with fewer gel applications.  The dosing regimens using the 64 
biological end-point (Arms4/5) proved equally efficacious as predefined treatment 65 
durations and may therefore be suitable for personalized AK treatment. 66 
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What’s already known about this topic? 68 
• Actinic keratosis (AK) occurs in sun-exposed skin areas and may progress to 69 
squamous cell carcinoma - if left untreated. 70 
• AK-treatments are often lengthy and demands high patient commitments. 71 
 72 
What does this study add? 73 
• Resiquimod gel 0.03/0.01% was effective as AK-treatment on balding scalp, 74 
forehead, or face. 75 
• Reduction of total number of gel applications (24>10) gave comparable clearance 76 
rates and may therefore simplify AK-treatments. 77 
• Dosing regimens using the biological end-point of erosion proved equally 78 
efficacious as predefined treatment duration and may therefore be suitable for 79 
personalized AK treatment. 80 
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INTRODUCTION 82 
Actinic keratosis (AK) occur predominantly on sun-exposed skin areas, appearing as 83 
irregularly shaped, scaly, and erythematous macules1,2.  The incidence rate of AK is 84 
increasing worldwide3, with fair skinned individuals living in sunny climates2.  Men are more 85 
frequently affected than women4, and prevalence increases with age5 with rates ranging 86 
from 11% to 26%2,6. 87 
AK-lesions are seen as part of a continuum along the path to the development of squamous 88 
cell carcinomas (SCC)7.  The rate for AK transformation to SCC is highly variable ranging 89 
from 0.1 to 10% or more8-11.  Therefore, most guidelines recommend AK to be treated2.  In 90 
recent years, topical therapies have become the preferred AK therapy1,12,3.  Although the 91 
immune-response modifier (IRM) imiquimod is an established treatment for AK, efforts are 92 
underway to increase efficacy, to shorten treatment duration and to reduce side effects for 93 
achieving an optimal AK treatment.  Resiquimod is an IRM, which based on its 94 
pharmacodynamic profile may potentially achieve greater efficacy than imiquimod13.  95 
Resiquimod activates myeloid dendritic cells in addition to plasmacytoid cells and induces 96 
more interleukin-12 and tumour necrosis factor than imiquimod3,14,15. 97 
A previous phase II study investigated the safety and efficacy of topical resiquimod gel in 98 
the treatment of AK-lesions14.  Resiquimod gel in concentrations of 0.01%, 0.03%, 0.06% or 99 
0.1% were applied 3x/week for 4 weeks in 1 or 2 treatment cycles.  The efficacy was high 100 
in all treatment groups, with overall complete clearance rates ranging from 77.1%-90.3%. 101 
Drug-related influenza-like symptoms were observed primarily at the higher concentrations.  102 
Treatment with 0.01% resiquimod gel demonstrated the best tolerability and provided the 103 
widest therapeutic window with an overall complete clearance rate of 77% and a severe 104 
erythema rate of 17%14. 105 
Against this background our primary objectives were to define the concentration and dosing 106 
schedule of resiquimod gel formulations at which complete clearance occurred, or at which 107 
a biological endpoint (clinical manifestation of skin erosion, i.e., the skin appears reddened, 108 
erosive, and weeping) was achieved with subsequent complete clearance.  A central 109 
element of this investigation was to reduce – compared to previous trials14,16 – the total 110 
number of gel applications during the treatment cycle and evaluate the suitability of using a 111 
biological endpoint to terminate treatment instead of a predefined treatment duration.  The 112 
secondary objectives were efficacy, local tolerability and safety of the various concentrations 113 
and dosing schedules of resiquimod gel.  114 
Topical Resiquimod 
Surber for authors 5 
METHODS 115 
TRIAL DESIGN 116 
In a prospective, randomized partly placebo-controlled, double blind (Arms1/2/3), phase II, 117 
dose-finding study, safety, tolerability and efficacy of topical resiquimod gel in patients with 118 
multiple AK was studied.  In two additional arms (Arms4/5), patients applied either 119 
resiquimod gel 0.01% or 0.03% 3 times weekly up to a biological end-point.  The study was 120 
approved by the Ethics Committees and regulatory authorities (Switzerland and Germany) 121 
and registered at ClinicalTrials.gov (NCT01583816). 122 
PATIENTS 123 
Between 5/2014 and 11/2014, 14 sites screened and enrolled patients.  Eligible were males 124 
and females over 18 years with ≥2 clinically (one biopsied) diagnosed AK-lesions (indicator 125 
lesion ≥6mm Ø) within a 25cm2 contiguous treatment area (balding scalp, forehead, or face), 126 
who gave written informed consent.  Patients with unstable significant medical conditions, 127 
active infections, immunosuppression or systemic cancer, autoimmune disorders, HIV, 128 
known thyroid abnormalities, depression, atopic dermatitis, rosacea, eczema, abuse, 129 
allergies or hypersensitivities to any product ingredients, pregnancy or lactation were 130 
excluded.  AK treatment related therapy-free time intervals were defined for the time prior to 131 
trial start.  Aside from the trial medication no other systemic or topical therapies of AK were 132 
allowed. 133 
INTERVENTIONS 134 
Patients self-administered the gel topically to pre-defined treatment areas, according to 135 
dosage and trial schedules (Tab.1).  Gel application took place prior to bedtime.  Efficacy, 136 
safety and local tolerability of treatments were investigated over ≤24 weeks.  Product dosage 137 
was defined as a string of gel corresponding to 250mg gel for 25cm2 i.e. 1μg/3µg resiquimod 138 
per cm2, respectively.  Treatment adherence was assessed by collecting and weighing 139 
treatment tubes at each patient visit. 140 
OUTCOMES 141 
Efficacy was evaluated based on clinical inspection of treatment area and AK-lesion counts.  142 
Lesions counts at visit1 were compared to lesion counts at trial end.  Complete clinical 143 
clearance (CCC) was reached if no previously existing lesion was present at trial end or 144 
after reaching the biological endpoint (manifestation of skin erosion, i.e. reddened, erosive 145 
and weeping skin) plus 8-week follow-up (Arms4/5).  Further efficacy endpoints were CCC 146 
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at start of the second treatment cycle (Arms1/2/3), disappearance of ≥ 75% of AK-lesions 147 
(PCC; partial clinical clearance) at trial end, histological proof of clearance of the indicator 148 
lesion at trial end, global efficacy judgment by investigator and patient by means of point 149 
scores (seven-point scale i.e., 1: significantly worse; 2: slightly worse; 3: no change; 4: 150 
slightly improved; 5: moderately improved; 6: significantly improved; 7: completely 151 
improved) at the starting point of the second treatment cycle (Arms1/2/3) and at trial end 152 
(Arms1/2/3/4/5).  Quality of life (QoL) was assessed with the Skindex-29 questionnaire at 153 
visit2 (baseline), after 1st treatment cycle for Arms1/2/3, and after reaching the biological 154 
endpoint for Arms4/5, as well at study end16,17.  The questionnaire encompasses the 155 
evaluation of three independent areas - symptoms, emotions, and functioning.  156 
Safety was assessed based on treatment-emerged adverse events (TEAE)/serious AE 157 
(SAE), local tolerability (burning, itching, pain) by means of symptom scoring (five-point 158 
scale i.e., 0: absent, 1: slight, 2: moderate, 3: severe, 4: very severe), systemic tolerability, 159 
blood chemistry, global tolerability judgment by investigator and patient by means of point 160 
scores (1-6) at the starting point of the second treatment cycle (Arms1/2/3) and at trial end 161 
(Arms1/2/3/4/5) and by the number of withdrawal from the trial.  Safety assessments were 162 
recorded at each patient visit. 163 
SAMPLE SIZE, RANDOMIZATION, BLINDING, STATISTICAL ANALYSIS 164 
Sample size was determined based on the objective to show superiority of resiquimod over 165 
placebo within maximally 24 weeks (chi-square test) related to the primary out-come - CCC.  166 
For superiority testing using two-tailed α of 0.05 (Type-1 error) and β of 0.20 (80% power), 167 
efficacy estimates of 25% for placebo (based on literature) and 70% for resiquimod 168 
(conservative calculation based on the earlier phase II study14), and a 2:1 allocation for 169 
resiquimod to placebo, the resulting sample size for comparing one active resiquimod Arm 170 
to placebo was 32 resiquimod patients and 16 placebo patients.  The total estimated sample 171 
size including all five active treatment arms plus the three matched placebos was 208. 172 
Patients meeting eligibility criteria were randomized to one of five treatment arms (Tab.1). 173 
In Arms1/2/3, patients were randomly assigned (2:1) to resiquimod gel or placebo.  For 174 
treatment Arms4/5, parallel group randomization (1:1) was applied.  Patients meeting 175 
eligibility criteria were assigned to consecutive numbers according to their enrolment and 176 
centre.  Treatment Arms1/2/3 were controlled each by their corresponding matching placebo 177 
(multi-placebo group design) to preserve blinding.  Treatment Arms4/5 were mutually 178 
blinded with no placebo control.  Arms4/5 were compared to placebo of Arm1.  A trial 179 
independent company prepared trial medication sets and randomly delivered the sets once 180 
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a patient was announced eligible by a centre.  The trial medication set (serially numbered) 181 
with the lowest number was then delivered.  Due to the fact that the length of the treatment 182 
was different (Tab.1) some treatment arms may be divined, e.g., Arm3. However, placebo 183 
and vera as well as drug concentration were always blinded.  Investigators, assessors, data 184 
analysts and patients remained blinded throughout the study.  Identity of resiquimod-185 
/placebo-treatments and resiquimod concentration was concealed using identical appearing 186 
tubes for all products. 187 
  188 
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RESULTS 189 
PATIENTS 190 
Fourteen study centres participated in this trial.  Most patients were enrolled in four study 191 
centres (two centres enrolled 39, two enrolled 24 patients). 192 
A total of 290 patients were screened and 218 met eligibility criteria and were randomized.  193 
One patient was enrolled but discontinued early and never administered study medication.  194 
Thus, 217 Caucasian patients (33 females; 184 males), 43-93 years (mean 70.9-74.1) who 195 
received at least one dose of trial medication were included in the Intention-To-Treat (ITT) 196 
and in the safety population (identical with ITT-population) analyses (Tab.2).  Thirty-seven 197 
had major protocol violation(s).  Therefore, 180 Caucasian patients (23 females; 157 males), 198 
47-90 years (mean 70.1-74.3) were included in the Per-Protocol (PP) population.  Protocol 199 
deviations were related to study inclusion or exclusion criteria, safety and efficacy 200 
assessments, conduct of trial or patient management.  The demographic characteristics of 201 
the patients at baseline were similar between study groups (Tab.2).  All patients had AK 202 
proven by histology.  Most patients were of skin photo-type II (n=134), 13 photo-type I, 67 203 
photo-type III and 2 photo-type IV (one missing information). 204 
OUTCOMES 205 
Primary Outcome 206 
In the ITT-population, the overall CCC-rate at study end was 67% (p=0.001 vs placebo), 207 
72% (p=0.004 vs placebo), 70% (p<0.001 vs placebo), 56% (p=0.009 vs placebo), and 74% 208 
(p<0.001 vs placebo) for treatment Arms1/2/3/4/5, respectively (Fig.1).  The P value in 209 
treatment Arms4/5 represents a Chi-Square test for differences between the active 210 
treatment Arm and placebo of Arm1.  In the PP-population, the overall CCC-rate at study 211 
end was 71% (p=0.001 vs placebo), 85% (p<0.001 vs. placebo), 72% (p<0.001 vs. placebo), 212 
56% (p=0.014 vs. placebo) and 79% (p<0.001 vs. placebo) for treatment Arms1/2/3/4/5, 213 
respectively (Fig.1). 214 
Secondary Outcomes 215 
In the ITT-population, the CCC-rate at the starting point of the second treatment cycle 216 
(Arms1/2/3) was 52% (p<0.001 vs placebo), 55% (p=0.002 vs placebo), and 52% (p=0.001 217 
vs placebo) for treatment Arms1/2/3, respectively (Fig.2).  In the PP-population, 62% 218 
(p<0.001 vs placebo), 63% (p<0.001 vs placebo) and 55% (p=0.002 vs placebo) of patients 219 
Topical Resiquimod 
Surber for authors 9 
treated with resiquimod gel showed complete clinical clearance after the first treatment cycle 220 
in treatment Arms1/2/3, respectively (Fig.2). 221 
In the ITT-population, PCC of AK-lesions (≥75%) was observed in 87% (p<0.001 vs 222 
placebo), 81% (p=0.004 vs placebo), 77% (p<0.001 vs placebo), 75% (p=0.002 vs placebo) 223 
and 78% (p=0.001 vs placebo) of patients of Arms1/2/3/4/5, respectively.  In the PP-224 
population 90% (p<0.001 vs placebo), 89% (p<0.001 vs placebo), 79% (p<0.001 vs 225 
placebo), 74% (p=0.004 vs placebo), and 83% (p<0.001 vs placebo) of patients treated with 226 
resiquimod gel (Arms1/2/3/4/5) showed PCC at study end (Fig.3). 227 
Histological proof of clearance at study end in the ITT-data set has shown that significantly 228 
more patients randomized to active drug were clear in comparison to placebo (of Arm1) in 229 
Arms 1 (67% vs. 13%, p<0.001), 4 (66% vs. 13%, p<0.001), and 5 (76% vs. 13%, p<0.001).  230 
In treatment Arms2/3 the difference to placebo was not significant (Arm2: 58% vs. 25%, 231 
p=0.031, Arm3: 69% vs. 40%, p=0.067).  In the PP-population, 63% (Arm2) to 77% (Arm5) 232 
of patients who administered resiquimod gel showed histological proof of clearance of the 233 
indicator lesion.  Results were significantly different from placebo (of Arm1) in Arm1 (65% 234 
vs. 13%, p=0.002), Arm4 (65% vs. 13%, p<0.001) and Arm5 (77% vs. 13%, p<0.001). 235 
Point scores of global judgments of efficacy by investigator were higher in all resiquimod 236 
treatment groups as compared to placebo.  At the starting point of the 2nd treatment cycle 237 
(i.e. after the 1st treatment cycle and an 8-week treatment-free interval), the investigators 238 
judged the efficacy as significantly better (ITT and PP-populations) in the resiquimod 239 
treatment groups of Arms 1/2/3 (ITT: p<0.001, p<0.001, p=0.007, PP: p<0.001, p<0.01, 240 
p=0.009).  The mean point scores improved further at study end in these Arms.  Compared 241 
to placebo, the efficacy was rated as “significantly improved” at study end in active groups 242 
of treatment Arms1/2/3 for the ITT and PP-populations (p<0.01).  At study end mean scores 243 
of active drug groups (Arms1/2/3/45) ranged from 4.6-6.4 in the ITT-population (moderately 244 
(p<0.001) to significantly (p<0.001) improved) and from 6.1-6.3 (significantly (p<0.01) 245 
improved) in the PP-population.  In the placebo groups the mean scores were 4.5-4.6 246 
(slightly to moderately improved).  At the starting point of the 2nd treatment cycle, ≥ 65% of 247 
the AK-lesions were judged as significantly to completely improved (ITT and PP-248 
populations) by the investigators.  At study end ≥80% and ≥79% of AK-lesions were 249 
considered to be significantly or completely improved in both the ITT and PP-population, 250 
respectively. 251 
Also, the global judgment of efficacy by patient mean point scores were higher in the active 252 
drug groups than in placebo groups at both the beginning of the 2nd treatment cycle and at 253 
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study end in all analysed populations.  Analogously, the mean point scores of the active 254 
drug groups rose at the end of study in treatment Arms1/2/3.  Compared to placebo, efficacy 255 
was rated as significantly improved (p≤0.001) at study end in Arms1/2/4/5 of both the ITT 256 
and PP-populations.  The mean scores at study end ranged from 5.9-6.2 (significantly 257 
improved) and from 5.9-6.4 (significantly improved) in the ITT and PP-populations, 258 
respectively.  In the placebo groups mean scores ranged from 4.4-4.9 (slightly to moderately 259 
improved) and from 4.4-4.8 (slightly to moderately improved) in the ITT and PP-populations, 260 
respectively.  At the starting point of the 2nd treatment cycle, patients judged efficacy as 261 
significantly improved in all active drug groups.  The percentage of patient’s global efficacy 262 
assessment judging efficacy as significantly to completely improved ranged from 59-78% 263 
after the 1st treatment cycle and from 73-85% at study end in the ITT-population.  In the PP-264 
population, percentages ranged from 59-81% and from 71-92% at both the beginning of the 265 
2nd treatment cycle and at study end, respectively. 266 
The QoL assessment (Skindex-29) has shown that in the ITT and PP-population, symptoms’ 267 
scores improved in all resiquimod treatment groups from baseline to visit 8 or to study end, 268 
with the highest improvement compared to baseline seen in Arm3 (mean score reduction -269 
3 (p<0.02) (ITT and PP)).  The same was observed regarding emotion scores with the 270 
highest, not statistically significant versus placebo, reduction in mean score values in Arm2 271 
(ITT-population: -2.3; PP-population: -2.5) and Arm4 (ITT-population: -2.0; PP-population: -272 
2.5). In the ITT- and PP-population, functioning scores improved in treatment Arm4 by -0.6 273 
(p=0.17) and -0.7 (p=0.26) from baseline to study end, respectively.  274 
Analysis of the treatment effect on the primary efficacy endpoint for possible confounders 275 
(gender, age: <65 years and ≥65 years, skin photo-type, and patient compliance (<75%; 276 
≥75%)), did not show statistically significant differences for any of them or for each 277 
confounder by treatment interaction term for any of the five active treatments versus 278 
placebo. 279 
SAFETY 280 
Patients of all treatment arms reported TEAEs (Tab.3).  TEAE of 128 (59%) patients were 281 
considered as related to trial drug (ADR; adverse drug reactions).  Within this class, 282 
“application site erythema” and “application scab” were the most frequently reported 283 
reactions with the highest incidences in treatment Arm5 (erythema: 52%, scab: 32%).  284 
Thirteen patients discontinued from trial due to TEAEs – five due to severe local skin 285 
reactions. 286 
  287 
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DISCUSSION 288 
Objectives of this trial were to define the concentration and dosing schedule of resiquimod 289 
gel at which CCC (no AK-lesion according to clinical evaluation in treatment area) occurred 290 
(Arms1/2/3), or at which a biological endpoint was achieved with subsequent CCC 291 
(Arms4/5). 292 
Efficacy was significantly higher in all resiquimod treatment groups compared to placebo 293 
with overall CCC-rates at the end of study ranging from 56% to 74% in the ITT-population.  294 
Results of all resiquimod treatment Arms were significantly better than placebo (p<0.01).  295 
Overall, the results were consistent with the hypothesis of 70% clearance with resiquimod 296 
versus 25% with placebo and with results from a previous study14 assessing resiquimod in 297 
AK.  Results were confirmed in the PP-population in which, the same overall CCC-rate 298 
ranged from 56% to 85%.  In the PP-analysis differences to placebo were significant in 299 
treatment Arms 1/2/3/5 (p<0.01). 300 
Regarding CCC-rates after 1st treatment cycle (i.e. 4-week treatment plus 8-week treatment-301 
free period), significantly higher percentages in comparison to placebo were observed in all 302 
active treatment groups assessed and in both analysis populations. 303 
Across all treatment groups, investigators and patients assessed the efficacy of resiquimod 304 
higher than the efficacy of placebo.  The mean score values of global judgment of efficacy 305 
by the investigators at study end were approximately 6 (significantly improved) with 306 
resiquimod and approximately 4.5 (slightly to moderately improved) with placebo.  QoL 307 
(Skindex-29) symptoms’ and emotions’ scores improved from baseline to study end in all 308 
resiquimod groups supporting the subjective efficacy of the product. 309 
Regarding safety, a higher percentage of resiquimod treated patients (77%) reported 310 
adverse events such as general disorders and administration site conditions in comparison 311 
to placebo (62%).  The highest indices of these events (mostly erythema and scab) were 312 
reported in treatment Arm5, which had the highest resiquimod-dosing scheme and the 313 
highest overall complete clearance (ITT analysis).  These events are seen in all therapies 314 
with IRM and can be interpreted as typical signs for immunostimulatory therapies.  The main 315 
reasons for discontinuation were general disorders and administration site conditions.  316 
Overall, the local tolerability of the trial medication was acceptable. 317 
The safety profile is consistent with previously completed clinical phase II and III trials 318 
including 2100 patients (resiquimod in various indications)13,14,16,19.  In these trials ADRs 319 
were primarily local skin reactions such as erythema, scab, oedema, erosion, ulceration and 320 
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vesicles.  Systemic ADRs included infections (application site pustules, nasopharyngitis, 321 
and application site infection) and nervous system disorders (headache, paresthesia). 322 
In the study conducted by Szeimies et al., influenza like symptoms were reported in one 323 
patient (3%) treated with resiquimod 0.03% gel14. In this study, three influenza-like side 324 
effects occurred in treatment Arm1/3. The symptoms are possibly related to cytokine 325 
release/induction, an activity associated with the proposed mechanism of action of 326 
resiquimod as an immune response modifier (IRM). 327 
One may compare our data with previous investigations related to topical AK-treatment.  In 328 
pooled analysis of trials using similar end points and clinical definitions for CCC and PCC, 329 
the rates of clearance were higher for ingenol mebutate (total of 3 applications for AK’s on 330 
face or scalp, evaluated at day 57 after trial initiation) than with placebo - 42.2% vs. 3.7% 331 
and 63.9% vs. 7.4%, respectively20.  For imiquimod 3.75% (up to 42 applications, evaluated 332 
at day 119 after trial initiation), the rates of clearance were also higher than with placebo – 333 
34.0% vs. 5.5% and 53.7% vs. 12.8%, respectively21.  For 5-fluorouracil 0.5% and salicylic 334 
acid 10% (up to 84 applications, evaluated at day 140 after trial initiation), the rate of CCC 335 
was higher than with placebo – 55.4% vs. 15.1%22.  In a recent trial a compounded mixture 336 
of 0.005% calcipotriol ointment (Taro Pharmaceuticals) with 5% 5-fluorouracil cream (Taro 337 
Pharmaceuticals) or Vaseline with 5% 5-fluorouracil cream at a 1:1 weight ratio (8 338 
applications, evaluated at day 56 after trial initiation), the rates of CCC and PCC of AK’s on 339 
the face were 27.0% vs. 0% and 80% vs. 0%, respectively23. 340 
For resiquimod Arms1/2/3 (24, 14, 10 applications, evaluated at day 168, 140, 126 after trial 341 
initiation), the rates of CCC and PCC were also higher than with placebo – 71-85% vs. 13-342 
21% and 79-90% vs. 27-36%, respectively.  And for resiquimod Arms4/5 (up to 24 343 
applications, evaluated at day 112 after trial initiation), the rates of these clearances were 344 
56-79% vs. 19% and 74-83% vs. 31%, respectively. 345 
Some limitations apply to this investigation.  To study the influence of a) drug concentration, 346 
b) dosing schedule, c) the usefulness of a biological endpoint as a marker for treatment 347 
cessation and d) to relate to a previous phase II study with the same resiquimod formulation 348 
(Arm1) the number of patients per arm was small (n=31-38).  There was no assignation of 349 
a direct placebo arm to the treatment Arms4/5.  The investigation was only focused on AK 350 
treatment of the balding scalp, forehead, and face.  The clinical clearance at study end 351 
proved the superiority of verum vs. placebo.  However, the histological proof of clearance in 352 
treatment Arm2/3 vs. placebo was not significant.  On the one side, this may be explained 353 
by the fact, that the treatment duration of Arm2/3 was shorter than in Arm1 (24 applications 354 
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vs. 14 applications vs. 10 applications (2 cycles)), on the other hand it emphasises the 355 
importance of the parallel use of clinical and histological means.  However, this statement 356 
is based on only one indicator lesion. 357 
Overall, resiquimod 0.03% is numerically more effective than the lower concentration of 358 
0.01%.  Effectiveness in the 3 placebo-controlled Arms1/2/3 was largely comparable 359 
between the treatment arms with CCC rates achieved with resiquimod compared to 360 
corresponding placebo.  However, the clinical response in Arms2/3 was reached with 361 
significantly less gel applications – 14 and 10 applications instead of 24, respectively.  In 362 
treatment Arm5 (same resiquimod strength as in treatment Arm1/2/3, treatment cessation 363 
elicited by biological endpoint) the average number of gel applications was 22.2 (median 364 
13). 365 
Taking comparable effectiveness of therapeutic regimens with the 0.03% resiquimod gel 366 
formulations, the two lowest dose/regimens/durations evaluated in this study (one treatment 367 
cycle: Arm2/0.03%, 7x/2 weeks and Arm3/0.03%, 5x/1 week) offer an effective topical IRM 368 
therapy with a considerable shorter treatment period compared to current IRM therapies.  369 
The dosing regimens using the biological end-point of erosion proved equally efficacious as 370 
fixed-time regimes promising a novel personalized approach in treating AK. 371 
  372 
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Table 1:  Trial Design, Interventions, Dosage and Trial Schedule 
 
Treatment Arm Strength  Treatment and Follow-Up Phases 
Week No.  -1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 
Visits  v1* v2*   v    v     v   v    v    v 
Arm1 0.03%  3x* 3x 3x 3x 8-week break 3x 3x 3x 3x 8-week break 
Placebo   3x 3x 3x 3x 8-week break 3x 3x 3x 3x 8-week break 
   1st Treatment Cycle 2nd Treatment Cycle 
 
Week No.  -1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
Visits  v1 v2 v    v     v v    v    v 
Arm2 0.03%  7x* 8-week break 7x 8-week break 
Placebo   7x 8-week break 7x 8-week break 
   1st Treatment Cycle 2nd Treatment Cycle 
 
Week No.  -1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 
Visits  v1 v2v    v     vv    v    v 
Arm3 0.03%  5x* 8-week break 5x 8-week break 
Placebo   5x 8-week break 5x 8-week break 
   1st Treatment Cycle 2nd Treatment Cycle 
 
Week No.  -1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 
Visits  v1 v2v v v v v v v v        v 
Arm4 0.01%  3x 3x 3x 3x 3x 3x 3x 3x 8-week break 
Arm5 0.03%  3x 3x 3x 3x 3x 3x 3x 3x 8-week break 
 
*v: visit, v1: screening visit, v2: baseline visit, 3x: applications on Mondays, Wednesdays and Fridays, 7x: applications on Mondays, Wednesdays, Fridays, Sundays, 
Tuesdays, Thursdays and Saturdays, 5x: applications on Mondays, Tuesdays, Wednesdays, Thursdays and Fridays,  
  
Table 2:  Demographic Characteristics of the Patients at Baseline. * 
ITT- Safety Population  
 Arm 1 Arm 2 Arm 3 Arm 4 Arm 5 
Resiquimod 
(N=31) 
Placebo 
(N=17) 
Resiquimod 
(N=33) 
Placebo 
(N=18) 
Resiquimod 
(N=31) 
Placebo 
(N=18) 
Resiquimod 
(N=38) 
Resiquimod 
(N=31) 
Age-yr*  73.9±6.9 73.9±10.1 72.8±8.1 71.3±8 72.7±6.9 72.3±9.1 70.9±8.7 74.1±9.5 
Male sex – no. (%) 25 (81) 14 (82) 29 (88) 16 (89) 26 (84) 15 (83) 34 (89) 25 (81) 
PP- Efficacy Population  
 (N=21) (N=16) (N=27) (N=14) (N=29) (N=15) (N=34) (N=24) 
Age-yr* 73.1±6.1 73.6±10.4 71.9±7.9 72.2±7.2 72.5±7 74.3±4 70.1±8.6 73.8±9.1 
Male sex – no. (%) 20 (95) 13 (81) 23 (85) 13 (93) 24 (83) 13 (87) 31 (91) 20 (83) 
 
* Plus-minus values are means ±SD.  
  
Table 3:  Overview of Treatment-Emergent Adverse Events 
 
Arm 1 Arm 2 Arm 3 Arm 4 Arm 5 
Resiquimod 
(N=31) 
Placebo 
(N=17) 
Resiquimod 
(N=33) 
Placebo 
(N=18) 
Resiquimod 
(N=31) 
Placebo 
(N=18) 
Resiquimod 
(N=38) 
Resiquimod 
(N=31) 
TEAEs 22 (71%) 11 (65%) 23 (70%) 11 (61%) 24 (77%) 11 (61%) 32 (84%) 26 (84%) 
SAEs 1 (3%) 1 (6%) 4 (12%) 3 (17%) 0 0 0 1 (3%) 
Discontinuations 
due to AEs 
7 (23%) 0 0 0 0 0 2 (5%) 4 (13%) 
ADRs 20 (65%) 3 (18%) 18 (55%) 6 (33%) 20 (65%) 5 (28%) 30 (79%) 26 (84%) 
SADRs 0 0 0 0 0 0 0 0 
Deaths 0 0 0 0 0 0 0 0 
 
TEAE: Treatment-Emergent Adverse Event, SAE: Serious Adverse Event, ADR: Adverse Drug Reaction, SADR: Serious Adverse Drug Reaction 
 Figure 1. Percentage of patients (ITT and PP population) showing complete clinical 
clearance at study-end. 
  
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Active Placebo Active Placebo Active Placebo Active Active
Arm 1 Arm 2 Arm 3 Arm 4 Arm 5
%
 o
f P
at
ie
nt
s 
Complete Clinical Clearance at Study-End
ITT
PP
 Figure 2: Secondary efficacy results (ITT- and PP population) - complete clinical 
clearance after 1st cycle. 
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 Figure 3: Secondary efficacy results (ITT- and PP population) - Partial clinical clearance of 
AK lesions (≥ 75%). 
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